Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
EditorialEditorial

An Historic Meeting

Antonio Moreira
PDA Journal of Pharmaceutical Science and Technology March 2015, 69 (2) 213-214; DOI: https://doi.org/10.5731/pdajpst.2015.01064
Antonio Moreira
Vice Provost for Academic Affairs UMBC 1000 Hilltop Circle Administration Building, Room 1001 Baltimore, MD 21250
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: journal@pda.org
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

On January 7th, 2015 I participated for the first time as a temporary voting member in a meeting of the Oncologic Drug Advisory Committee (ODAC) of the Food and Drug Administration (FDA). Being the first ODAC meeting that I participated in, it was of special meaning to me. However, this meeting was not another “regular” ODAC meeting.

As Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER) at the FDA, stated in her opening remarks, this was an historic meeting because the ODAC set about to discuss the very first biosimilar product submission to the FDA for possible licensure in the U.S. The specific drug is known as EP2006 and it was developed by Sandoz, a unit of the Swiss company Novartis, as a biosimilar product to Neupogen, also known as filgrastim. Neupogen is manufactured by the American company Amgen. EP2006 has been approved by the European Medicines Agency (EMA) since 2009 under the name Zarzio; it is now approved in over 60 countries and has over 7.5 million patient-days of exposure (according to the Sandoz briefing at the meeting).

The availability of generic versions of traditional small-molecule drugs dates back to 1984 when the Hatch-Waxman Act was enacted. An equivalent pathway for approving close copies of biological drugs reaching patent expiration did not exist in the U.S. until March 23, 2010, when a new regulatory pathway for the so-called biosimilars was authorized as the Biologics Price Competition and Innovation Act (BPCI Act) was passed as part of the Affordable Care Act and then signed by President Obama into law.

At the ODAC meeting on January 7, Dr. Leah Christl, associate director for therapeutic biologics, OND Therapeutic Biologics and Biosimilars Team at CDER, provided an overview of the regulatory pathway and the FDA's guidance for development and approval of biosimilar products in the U.S. In her overview, Dr. Christl highlighted that biosimilarity means that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency of the product. Also highlighted was that from a biosimilar product development perspective, the goal is to demonstrate biosimilarity between the proposed product and the reference product and not to independently establish safety and effectiveness of the proposed product, as such was already established for the reference product.

After a full day of presentations and discussions by representatives of the FDA and the applicant and an open public hearing, the ODAC members were asked by the FDA to discuss and vote on the following questions:

DISCUSSION: Does the committee agree that EP2006 is highly similar to the reference product, U.S.-licensed Neupogen, notwithstanding minor differences in clinically inactive components?

DISCUSSION: Does the committee agree that there are no clinically meaningful differences between EP2006 and U.S.-licensed Neupogen?

VOTE: Does the committee agree that based on the totality of evidence, EP2006 should receive licensure as a biosimilar product for each of the five indications for which U.S.-licensed Neupogen is currently licensed?

During the day's proceedings, I was struck by the importance of CMC (chemistry, manufacturing, and controls) topics as a key component of the discussions. While clinical issues were certainly considered, aspects of biomolecule function, analytical characterization, and testing were central to the discussion. The meeting was an interesting introduction to the totality-of-the-evidence approach from the FDA guidance.

The final vote by the ODAC members was 14-0, with no abstentions. Following this vote, the FDA has announced on March 6th, 2015 the approval of Zarxio (filgrastim-sndz) as the first biosimilar product approved in the US. Dr. Christl is quoted on the FDA website accessed on the same day as follows: “Patients can be assured that they'll be able to rely upon the safety and effectiveness of an FDA-approved biosimilar, just as they can rely on the reference product that the biosimilar was compared to.” Indeed, an exciting new chapter in the history of biologics in the US is unfolding with hundreds of biosimilar products currently in development worldwide and whose sponsors will look carefully at the outcomes from the January 7th meeting and the subsequent FDA decision on March 6th.

Stay tuned!

  • © PDA, Inc. 2015
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 69 (2)
PDA Journal of Pharmaceutical Science and Technology
Vol. 69, Issue 2
March/April 2015
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
An Historic Meeting
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
6 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
An Historic Meeting
Antonio Moreira
PDA Journal of Pharmaceutical Science and Technology Mar 2015, 69 (2) 213-214; DOI: 10.5731/pdajpst.2015.01064

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
An Historic Meeting
Antonio Moreira
PDA Journal of Pharmaceutical Science and Technology Mar 2015, 69 (2) 213-214; DOI: 10.5731/pdajpst.2015.01064
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • July-August 2020 Issue
  • PDA's 2020–2026 Strategic Plan
  • Editor's Note
Show more Editorial

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2021 PDA Journal of Pharmaceutical Science and Technology ISSN: 1079-7440

Powered by HighWire